NCT03397706 2025-03-20
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Viracta Therapeutics, Inc.
Phase 1/2 Completed
Clinical Trials
5 trialsNCT01441063 2020-10-27
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01255644 2015-07-21
VGCV-CLL
Medical University of Vienna
Phase 4 Completed
NCT00217503 2013-06-20
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00562770 2012-07-31
Oral Valganciclovir Versus Valacyclovir
M.D. Anderson Cancer Center
Phase 2 Completed